Olmesar

📦 Každá objednávka je pokryta naší Zárukou opětovného odeslání — pokud vaše zásilka nedorazí do 20 pracovních dnů, přeposíláme ji.

Proč objednávat z MedsBase

Naše generické léky pocházejí od výrobců certifikovaných WHO-GMP a jsou expedovány po celém světě v diskrétním, nenápadném balení – na vnější straně balíku není uveden název léku. Platby kartou jsou směrovány prostřednictvím regulovaného procesoru (popisky na výpisu zahrnují regulovaného procesora plateb kartou – nikdy “MedsBase” nebo název léku). Přijímáme také kryptoměny a bankovní převody SEPA. Každá objednávka je zajištěna naší politikou přeposlání.

What Is Olmesar?

Olmesar is an oral 20 / 40 mg olmesartan tablet from Cipla, supplied in 30-180 tablets. Introduced 2002 (Daiichi-Sankyo as Benicar / Olmetec). Among the more potent ARBs on milligram basis. Olmesartan medoxomil is a prodrug rapidly hydrolysed in the gut to active olmesartan. Half-life 13 hours; once-daily dosing with stable 24-hour BP control.

How Olmesartan Lowers Blood Pressure

ARBs block the angiotensin II type 1 (AT₁) receptor directly, preventing angiotensin II from binding and exerting its vasoconstrictor and aldosterone-releasing effects. This is one receptor downstream of where ACE inhibitors act (which block angiotensin II formation) and produces equivalent clinical effects:

• Direct arterial vasodilation — lower systemic vascular resistance = lower blood pressure
• Reduced aldosterone secretion — less sodium and water retention
• Reduced sympathetic nervous system activation
• Improved endothelial function and reduced ventricular remodelling — the vascular-protective mechanism beyond simple BP lowering
• NO bradykinin accumulation — this is the key clinical difference from ACE inhibitors. ARBs do NOT cause the dry cough that affects up to 20% of ACEi users, because they don’t interfere with bradykinin metabolism.

Clinical consequence of this mechanism: ARBs achieve equivalent BP control to ACE inhibitors with lower rates of cough (0-3% vs 20% for ACEi) and angioedema (roughly 30-50% lower than ACEi, though not zero).

Approved and Evidence-Based Uses

• Hypertension — primary indication; first-line per international guidelines
• Hypertension monotherapy or step-up after diuretic
• Hypertension in patients needing potent single-agent BP control
• Not preferred in heart failure (valsartan or candesartan have direct HF-REF evidence)
• Intolerance to ACE inhibitors (cough, less commonly angioedema) — standard switch target

Pivotal trial evidence: ROADMAP trial (2011) — olmesartan delayed microalbuminuria onset in type 2 diabetes (controversial: more cardiovascular deaths in olmesartan arm, unexplained). ORIENT — Japanese diabetic nephropathy trial, similar cardiovascular signal. Use with careful risk-benefit discussion in diabetics with overt CVD.

Olmesar Dosage

Hypertension:

• Starting dose: 20 mg once daily
• Target dose: 20-40 mg once daily
• Maximum: 40 mg once daily
• Titrate every 2-4 weeks; full antihypertensive effect at 3-6 weeks

Heart failure: Not primary HF indication; usually avoided in HF-REF in favour of valsartan or candesartan

Administration: once daily, with or without food. Take at the same time each day for stable BP control.

Monitorování:

• Baseline: urea, electrolytes (particularly potassium), creatinine, eGFR. Home BP baseline.
• After 1-2 weeks: repeat U&E. Small rise in creatinine (up to 30%) is expected and acceptable. Small rise in potassium is common.
• After dose increase: repeat U&E at 1-2 weeks.
• Ongoing: annual U&E once stable.
• Stop and investigate: creatinine rise >30%, eGFR fall >25%, potassium >5.5, symptomatic hypotension.
• Olmesartan-specific: investigate any chronic unexplained diarrhoea, weight loss, or villous-atrophy features — rare but recognised sprue-like enteropathy.

Discontinuation: no withdrawal syndrome; however, abrupt stop causes BP rebound over days. Taper over 1-2 weeks when stopping.

Vedlejší účinky

Common (>1%, usually mild):

• Dizziness, postural hypotension (usually mild; more common at start of therapy)
• Mild hyperkalaemia
• Expected small creatinine rise (up to ~30% is acceptable; intrarenal haemodynamic change, not nephrotoxicity)
• Fatigue, headache
• Upper respiratory symptoms, nasopharyngitis
• Back pain, muscle cramps

Uncommon but important:

• Angioedema — lower rate than with ACE inhibitors but still possible. Incidence ~0.1%. Do NOT use an ARB if the patient has a documented history of angioedema to an ACE inhibitor in the first 4 weeks; longer-term cautious use often acceptable.
• Severe hyperkalaemia — particularly with potassium-sparing diuretics (spironolactone), potassium supplements, NSAIDs, or CKD
• Acute kidney injury in bilateral renal artery stenosis — same mechanism as ACE inhibitors
• First-dose hypotension in volume-depleted patients (e.g. on high-dose diuretics, severe HF)
• Sprue-like enteropathy (olmesartan-specific) — FDA 2013 warning. Chronic diarrhoea, weight loss, villous atrophy mimicking coeliac. Resolves after stopping olmesartan.

Kontraindikace

• Pregnancy — ABSOLUTE contraindication at all trimesters. Same teratogenic profile as ACE inhibitors. Stop immediately on pregnancy; switch to labetalol, methyldopa, nifedipine, or hydralazine.
• History of angioedema with any ACE inhibitor or ARB (within 4 weeks)
• Bilateral renal artery stenosis or stenosis in a single functioning kidney
• Severe hepatic impairment (Child-Pugh C) — particularly for prodrug ARBs
• Hyperkalaemia >5.5 mmol/L at baseline
• Concurrent use of sacubitril/valsartan (Entresto) — 36-hour washout required when switching
• Concurrent aliskiren in diabetes or CKD (ALTITUDE trial harm)
• Concurrent ACE inhibitor — ONTARGET trial harm without benefit
• Hypersensitivity to olmesartan

Breastfeeding: avoid in the first weeks after delivery of a premature infant. Long-term use in established breastfeeding is generally considered acceptable given low milk transfer, but alternative antihypertensives (propranolol, nifedipine) are preferred when possible.

Interakce s léčivy

• Potassium-sparing diuretics (spironolactone, eplerenone, amiloride, triamterene) — additive hyperkalaemia; monitor closely
• Potassium supplements and salt substitutes — hyperkalaemia risk
• NSAID — reduce antihypertensive effect and increase AKI risk (particularly the “triple whammy”: ARB + diuretic + NSAID)
• Lithium — ARBs reduce lithium clearance; monitor levels
• ACE inhibitory — do NOT combine (ONTARGET harm)
• Sacubitril/valsartan (Entresto) — do not combine; 36-hour washout
• Aliskiren — avoid in diabetes or CKD (ALTITUDE harm)

ARB Class at a Glance

ARB vs ACE Inhibitor — When to Choose an ARB

ACE inhibitors (ramipril, enalapril, lisinopril, perindopril) and ARBs act on the same renin-angiotensin pathway and produce equivalent BP-lowering and cardiovascular protection. Choose an ARB when:

• ACE-inhibitor cough has appeared (up to 20% of users; most common reason for switch)
• Past ACE-inhibitor angioedema (use an ARB cautiously, not within 4 weeks of the angioedema episode)
• Some patients prefer the once-daily profile of long-acting ARBs like telmisartan for smooth 24-hour control
• Specific molecule indications — losartan for HTN+gout, irbesartan for type 2 diabetic nephropathy, valsartan as a precursor to ARNI in HF

Do NOT combine ARB + ACE inhibitor. ONTARGET trial (2008) showed the combination produces MORE adverse events (hyperkalaemia, AKI, hypotension) without any additional cardiovascular benefit. If a patient is on both, stop one.

Skladování

Store Olmesar below 25°C in the original blister pack. Keep out of reach of children.

Často kladené dotazy

How long does Olmesar take to lower blood pressure?

Initial BP drop within 1-2 hours; full antihypertensive effect at 3-6 weeks. Measure home BP at the same time each day to track response. If BP has not come to target at 6 weeks, either increase dose or add a second-class agent (CCB or thiazide are the standard add-ons to an ARB).

I switched from an ACE inhibitor because of cough — will my cough go away?

Yes. The ACE-inhibitor cough is caused by bradykinin accumulation; ARBs do not raise bradykinin. The cough typically resolves within 1-4 weeks of stopping the ACE inhibitor. If your cough persists beyond 6 weeks after switching to Olmesar, investigate an alternative cause (reflux, postnasal drip, asthma).

Can I take Olmesar in pregnancy?

No — ARBs are absolutely contraindicated in pregnancy, same as ACE inhibitors. They cause fetal renal agenesis, oligohydramnios, pulmonary hypoplasia, and skull defects. Stop immediately if pregnancy occurs. Women of childbearing potential should use reliable contraception; for those planning pregnancy, switch to labetalol, methyldopa, or nifedipine pre-conception.

My creatinine went up a bit after starting Olmesar — should I stop?

A creatinine rise of up to 30% within the first 1-2 weeks is expected and acceptable. It reflects normal intrarenal haemodynamic adjustment as angiotensin-II-mediated efferent arteriolar tone is removed. A rise >30% suggests bilateral renal artery stenosis, volume depletion, or NSAID interaction and requires investigation (stop the drug, get renal imaging, review concurrent medication).

Should I avoid potassium-rich foods on Olmesar?

Moderate intake of potassium-rich foods (bananas, oranges, spinach, avocado, potatoes) is fine for most users. Avoid potassium supplements (slow-K) and potassium-containing salt substitutes unless specifically prescribed — these can cause dangerous hyperkalaemia when combined with ARBs, particularly in CKD or with potassium-sparing diuretics.

Can I combine Olmesar with my other BP medications?

Yes — ARBs combine well with calcium-channel blockers (amlodipine), thiazide diuretics (HCTZ), and beta-blockers (bisoprolol, metoprolol succinate). Do NOT combine an ARB with an ACE inhibitor (ramipril, lisinopril, etc.) — ONTARGET trial showed harm without benefit.

Can I take ibuprofen with Olmesar?

Occasional short-term use is usually acceptable; chronic daily NSAIDs (ibuprofen, diclofenac, naproxen) reduce the antihypertensive effect of ARBs AND substantially raise the AKI risk — particularly when combined with a diuretic (the “triple whammy”). For chronic pain, paracetamol is safer; for inflammation, discuss alternatives.

Is Olmesar lifelong?

For most patients with essential hypertension, yes — antihypertensive therapy is lifelong because stopping returns BP to pre-treatment levels within days to weeks. Some patients lose their hypertension through significant weight loss, reduced alcohol intake, or better sleep; their physician may then trial a careful taper under BP monitoring. Never stop Olmesar without medical advice.

Co když vynechám dávku?

Take the missed dose as soon as you remember, unless it is nearly time for the next dose — in that case skip the missed dose and continue your normal schedule. Do not double up. A single missed dose will not meaningfully affect long-term BP control.

Where can I buy Olmesar online?

You can buy Olmesar (olmesartan 20 / 40 mg, 30-180 tablets) from MedsBase with discreet packaging and worldwide shipping.

Related Antihypertensives on MedsBase

• Amlode — Amlodipine CCB
• Cosart-H — Losartan + HCTZ
• Losatec-H — Losartan + HCTZ
• Olmezest-AM — Olmesartan + Amlodipine
• Ramcor — Ramipril (ACEi alternative)
• Telmaheal — Telmisartan 20/40/80 mg
• Browse all High Blood Pressure Medications

Související alternativy

Další produkty v Chronická onemocnění které zákazníci také prohlížejí:

• Methylene Blue Injection
• Choltran Sachet
• Predniheal
• Tachyra
• Emanzen Forte

Další možnosti v léčbě vysokého krevního tlaku

Řazeno podle nedávného objemu objednávek na MedsBase — co si ostatní zákazníci v této kategorii vybírají.

Telmaheal

US$9.00 – US$36.00Cenové rozpětí: US$9.00 až US$36.00

Losar

US$6.53 – US$29.25Cenová hladina: 6,53 US$ až 29,25 US$

Amlode

US$5.50 – US$24.00Cenová hladina: 5,50 US$ až 24,00 US$

Minoxytop

US$22.00 – US$170.00Cenová hladina: 22,00 US$ až 170,00 US$